Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

MD-0727 safe in healthy volunteers

July 5, 2006

Ezetimibe adds to rosuvastatin efficacy in hypercholesterolemic patients

July 5, 2006

Ethics approval for phase I study of Phosphagenics' transdermal insulin product

July 5, 2006

Treatment completed in phase I/II study of Aastrom's Tissue Repair Cells

July 5, 2006

Pivotal trial for Auxilium's testosterone transmucosal film in hypogonadism

July 5, 2006

New River files IND for NRP-409

July 4, 2006

New KB-2115 formulation completes phase I study

July 4, 2006

Phase IIa study of oleoyl-estrone now dosing patients

July 4, 2006

Eisai licenses SERMS to Radius Health

July 4, 2006

King and Depomed to copromote Glumetza

July 3, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...